Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

zundapp125 Dec. 5 at 11:27 AM

$IGC stasera annuncio sui finalisti del concorso piatttaforma di diagnostica alzheimer A.I. di igc.

0 · Reply

dwiz5 Dec. 3 at 11:48 PM

$IGC added up to 25K shares add when I can. G/L waiting for phase 3

0 · Reply

Honeybear89 Dec. 3 at 12:42 PM

$IGC waiting for this to hit .27 to buy again for the next bounce

1 · Reply

Buttermaker007 Nov. 28 at 1:59 PM

$IGC we got news ! Now let’s get to $1.25

0 · Reply

IGC Nov. 26 at 10:04 PM

$IGC IGC Pharma is advancing its research efforts with MINT-AD, our multimodal AI platform, to analyze global aging datasets and explore how socioeconomic and health-related factors may relate to cognitive outcomes across diverse populations. By integrating data from 14 large-scale international longitudinal studies, this work aims to provide additional insights into aging trends and contribute to broader research efforts focused on Alzheimer’s disease. This initiative reflects our continued commitment to supporting data-driven approaches that enhance understanding of cognitive health in aging populations. Read the full press release: https://lnkd.in/e_ZGcGz9 #IGCPharma #AlzheimersResearch #AIInnovation #DataScience #PrecisionMedicine

0 · Reply

VizTheWin Nov. 26 at 6:39 PM

$IGC let’s go turd

0 · Reply

krishkk Nov. 26 at 5:28 PM

$IGC give me a thanksgiving gift 🎁

0 · Reply

Marcobecco Nov. 24 at 8:46 PM

$IGC when please 🙏 ask for a friend

0 · Reply

Buttermaker007 Nov. 23 at 11:22 AM

$IGC we need a catalyst , something huge ! Reclassification and Alzheimer’s study to be successful

1 · Reply

VizTheWin Nov. 20 at 6:01 PM

$IGC sum ting wong

0 · Reply

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 10 days ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 8:30 AM EST - 18 days ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 13, 2025, 9:00 AM EST - 22 days ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 25 days ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 4 weeks ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 6 weeks ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 7 weeks ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 7 weeks ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 27, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 25, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 19, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 12, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 5, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Jul 23, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 10, 2025, 3:10 PM EDT - 5 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 5 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 5 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 7 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 7 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 1, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Mar 26, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 20, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 17, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 12, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 10, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 4, 2025, 9:00 AM EST - 9 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Feb 20, 2025, 9:00 AM EST - 10 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 18, 2025, 8:30 AM EST - 10 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 11, 2025, 8:30 AM EST - 10 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Jan 28, 2025, 8:30 AM EST - 11 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 13, 2025, 8:30 AM EST - 11 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 8, 2025, 8:30 AM EST - 11 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Dec 19, 2024, 7:00 PM EST - 1 year ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 2, 2024, 8:30 AM EST - 1 year ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Nov 25, 2024, 8:30 AM EST - 1 year ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 14, 2024, 8:30 AM EST - 1 year ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 6, 2024, 8:30 AM EST - 1 year ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

zundapp125 Dec. 5 at 11:27 AM

$IGC stasera annuncio sui finalisti del concorso piatttaforma di diagnostica alzheimer A.I. di igc.

0 · Reply

dwiz5 Dec. 3 at 11:48 PM

$IGC added up to 25K shares add when I can. G/L waiting for phase 3

0 · Reply

Honeybear89 Dec. 3 at 12:42 PM

$IGC waiting for this to hit .27 to buy again for the next bounce

1 · Reply

Buttermaker007 Nov. 28 at 1:59 PM

$IGC we got news ! Now let’s get to $1.25

0 · Reply

IGC Nov. 26 at 10:04 PM

0 · Reply

VizTheWin Nov. 26 at 6:39 PM

$IGC let’s go turd

0 · Reply

krishkk Nov. 26 at 5:28 PM

$IGC give me a thanksgiving gift 🎁

0 · Reply

Marcobecco Nov. 24 at 8:46 PM

$IGC when please 🙏 ask for a friend

0 · Reply

Buttermaker007 Nov. 23 at 11:22 AM

$IGC we need a catalyst , something huge ! Reclassification and Alzheimer’s study to be successful

1 · Reply

VizTheWin Nov. 20 at 6:01 PM

$IGC sum ting wong

0 · Reply

Golferhack12 Nov. 19 at 8:53 PM

$IGC breaking down on low volume very negative

0 · Reply

TritiumH3 Nov. 19 at 4:31 AM

$IGC this one touched me 😍. I fell in love with trading $IGC

0 · Reply

krishkk Nov. 18 at 8:59 PM

$IGC holding 25k lets see if it makes me poor or some gains lets hope it goes $0.5 above my avg

0 · Reply

dwiz5 Nov. 17 at 5:19 PM

$IGC added two K more today total 20K shares it coming question is when G/L

2 · Reply

Buttermaker007 Nov. 17 at 1:41 PM

$IGC what in the actual ? Let’s get some volume and investors ! Also, when is reclassification of cannabis

0 · Reply

Vote4Pedro2 Nov. 17 at 10:55 AM

$IGC Today's the day

0 · Reply

VizTheWin Nov. 15 at 12:32 AM

$IGC turd

0 · Reply

IGC Nov. 14 at 2:34 PM

$IGC U.S. patent expands IGC Pharma’s intellectual property portfolio and supports our continued work to develop safer, more effective treatments that address both behavioral symptoms and core disease mechanisms of Alzheimer’s disease. #AlzheimersResearch #HealthCareInnovation #ClinicalResearch #NeuroScience #IGCPharma

0 · Reply

krishkk Nov. 14 at 11:31 AM

$IGC going down day by day is not a good sign…. 😒

0 · Reply

Honeybear89 Nov. 13 at 6:07 PM

$IGC pretty much the only stock or crypto that’s green today😅

1 · Reply

1AMBITIOUSSAVAGE Nov. 13 at 4:59 PM

$SLRX is going to boom 0 shorts available 70.77% short interest $IGC $CODX $NVVE

0 · Reply

HS_ Nov. 13 at 2:32 PM

$IGC Alzheimer’s Treament Patent Granted 🌟

0 · Reply

Market Cap	28.05M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	446,800
Avg Vol	736,274
Day's Range	N/A - N/A
Shares Out	92.87M
Stochastic %K	25%
Beta	0.24
Analysts	Sell
Price Target	$3.75